Quote | Synaptogenix Inc. (OTCMKTS:SNPX)
Last: | $1.56 |
---|---|
Change Percent: | 15.56% |
Open: | $1.35 |
Close: | $1.56 |
High: | $1.6 |
Low: | $1.27 |
Volume: | 38,601 |
Last Trade Date Time: | 05/18/2021 04:42:35 am |
News | Synaptogenix Inc. (OTCMKTS:SNPX)
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics PR Newswire Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK , April 9, 202...
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing PR Newswire Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" o...
Message Board Posts | Synaptogenix Inc. (OTCMKTS:SNPX)
Subject | By | Source | When |
---|---|---|---|
I agree in principal but unless NIH funds | runncoach | investorshub | 04/14/2023 6:55:44 PM |
I don't think Bryostatin is done. I | Battle Ready | investorshub | 04/14/2023 4:34:29 PM |
If Bryostatin is done for work and I | runncoach | investorshub | 04/14/2023 4:22:05 PM |
I had only kept 1000 shares of Petros, | Battle Ready | investorshub | 04/14/2023 4:19:14 PM |
Anyone that still has shares of petros from | runncoach | investorshub | 04/14/2023 4:10:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Inc. Company Name:
SNPX Stock Symbol:
OTCMKTS Market:
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics PR Newswire Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK , April 9, 202...
Synaptogenix Inc (NASDAQ:SNPX) shares are trading slightly higher Thursday morning after the company announced a 1-for-25 reverse stock split. This...
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing PR Newswire Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" o...